ANZUP trials – kidney

ANZUP is currently running a number of kidney cancer trials. For more details information about these trials, go to the ANZUP kidney cancer trials web page: https://anzup.org.au/clinical-trials/kidney-cancer-trials/

Principal Investigator:

Professor Ian Davis

RAMPART

ANZUP 1606

Status: Open & recruiting

Location: Australia & Internationally

Activated sites: 9 (Australian) • Patients recruited: 24

Patients required: Australian recruitment target - 200pts (total international recruitment 1750pts)

Removing the kidney (or part of a kidney) by surgery is currently the best treatment if you have kidney cancer. The current standard treatment after surgery is ‘active monitoring’. This means no further treatment, but having regular checks so that if the cancer does come back further treatment options can be considered as early as possible.

Surgery, together with ongoing regular follow-up and observation, is the standard approach for people diagnosed with kidney cancer that has required removal of the kidney (or part of a kidney) by surgery. For some people the cancer may return which is when other treatment is offered. We are aiming to find out whether taking one drug (durvalumab) or a combination of two drugs (durvalumab and tremelimumab) can prevent or delay kidney cancer coming back.

For more information, please refer to

https://anzup.org.au/clinical-trial/rampart/ Current locations for the RAMPART trial:

NSW

• Calvary Mater Newcastle • Campbelltown Hospital • Concord Repatriation General Hospital

VIC

• Eastern Health (Box Hill Hospital) • Monash Health • St Vincent’s Hospital Melbourne

QLD

• Mater Cancer Care Centre, Mater Misericordiae Ltd • Sunshine Coast University Hospital

SA

• Royal Adelaide Hospital